Thomas Charles Reilly
Net Worth
Last updated:
What is Thomas Charles Reilly net worth?
The estimated net worth of Mr. Thomas Charles Reilly is at least $937,929 as of 3 Mar 2022. He owns shares worth $204,164 as insider, has earned $51,405 from insider trading and has received compensation worth at least $682,360 in Cara Therapeutics, Inc..
What is the salary of Thomas Charles Reilly?
Mr. Thomas Charles Reilly salary is $170,590 per year as Chief Financial Officer in Cara Therapeutics, Inc..
How old is Thomas Charles Reilly?
Mr. Thomas Charles Reilly is 53 years old, born in 1972.
What stocks does Thomas Charles Reilly currently own?
As insider, Mr. Thomas Charles Reilly owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Cara Therapeutics, Inc. (CARA) | Chief Financial Officer | 37,811 | $5.4 | $204,164 |
What does Cara Therapeutics, Inc. do?
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Thomas Charles Reilly insider trading
Cara Therapeutics, Inc.
Mr. Thomas Charles Reilly has made 2 insider trades between 2021-2022, according to the Form 4 filled with the SEC. Most recently he sold 2,044 units of CARA stock worth $23,261 on 3 Mar 2022.
The largest trade he's ever made was exercising 2,044 units of CARA stock on 3 Mar 2022. As of 3 Mar 2022 he still owns at least 37,811 units of CARA stock.
Cara Therapeutics key executives
Cara Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Derek T. Chalmers D.Sc., Ph.D. (61) Co-Founder & Senior Advisor
- Dr. Frédérique Menzaghi (59) Chief Scientific Officer and Senior Vice President of R&D
- Dr. Joana Goncalves (51) Chief Medical Officer
- Mr. Christopher A. Posner (55) Pres, Chief Executive Officer & Director
- Mr. Richard Makara (54) Vice President, Head of Accounting, Controller & Principal Accounting Officer
- Mr. Scott M. Terrillion (62) Chief Compliance Officer, Gen. Counsel & Corporation Sec.
- Mr. Thomas Charles Reilly (53) Chief Financial Officer